Phaseline

Companies › Alessa Therapeutics

Alessa Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 19 registered trials: 7 Phase 1, 7 Phase 2, 4 Phase 3, 1 Phase 4; Oncology, Genitourinary; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bicalutamide
Androgen Receptor antagonist
ARPhase 1Prostate Adenocarcinoma; Androgen Deprivation Therapy; Prostate Cancer; Castration Levels of Testosterone …Apr 2027
Enzalutamide
Androgen Receptor antagonist
ARPhase 1Prostate AdenocarcinomaDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03090165BicalutamidePhase 1Triple Negative Breast CancerOncologyOct 2026
NCT02605486BicalutamidePhase 1Metastatic Breast Cancer (MBC)OncologyNov 2026
NCT07393867BicalutamidePhase 2Intermediate Risk Prostate CancerOncologyDec 2026
NCT03650894BicalutamidePhase 2Breast Neoplasm FemaleOncologyDec 2026
NCT00223145BicalutamidePhase 3Prostate CancerOncologyDec 2026
NCT00544830BicalutamidePhase 2PSA Level Greater Than TwoOncologyFeb 2027
NCT04943536BicalutamidePhase 1Prostate AdenocarcinomaOncologyApr 2027
NCT05327647BicalutamidePhase 2Non-Muscle Invasive Bladder CancerOncologyMay 2027
NCT05095207BicalutamidePhase 1Breast CancerOncologyJun 2027
NCT06222593BicalutamidePhase 1Carcinoma, Renal CellOncologyJul 2027
NCT05100472BicalutamidePhase 2Prostate CancerOncologyOct 2027
NCT06365788BicalutamidePhase 2Triple Negative Breast NeoplasmsOncologyDec 2027
NCT07117851BicalutamidePhase 2Extramammary Paget DiseaseOncologyDec 2027
NCT05521698BicalutamidePhase 1Non-Muscle Invasive Bladder Urothelial CarcinomaOncologyJun 2028
NCT07848828BicalutamidePhase 4Androgen Deprivation TherapyGenitourinaryJul 2028
NCT06257693EnzalutamidePhase 1Prostate AdenocarcinomaOncologyDec 2028
NCT05019846BicalutamidePhase 3Prostate CancerOncologyDec 2029
NCT05781217BicalutamidePhase 3Prostate CancerOncologyDec 2032
NCT03678025BicalutamidePhase 3Castration Levels of TestosteroneOncologyApr 2033

Targets

AR (2)

Companies with the same targets

Johnson & Johnson (Janssen) Novartis Astellas Sun Pharmaceutical Industries Hansoh BioMedical R&D Company Merck & Co. (MSD) Bayer Qilu Pharmaceutical Aragon Pharmaceuticals AstraZeneca

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.